Skip to main content
. Author manuscript; available in PMC: 2015 Oct 15.
Published in final edited form as: Clin Cancer Res. 2012 Feb 28;18(8):2210–2219. doi: 10.1158/1078-0432.CCR-11-2413

Figure 4. MLN8237 plus Vincristine plus Rituximab is synthetic lethal and curative in a mouse xenograft model of MCL.

Figure 4

Figure 4

(A). Granta-519 xenograft mice (n=12 per cohort) were treated with saline (control), M 30 mg/kg + R 10 mg/kg, M 30 mg/kg + V 0.375 mg/kg and M 30 mg/kg + V 0.375 mg/kg + R 10 mg/kg. MLN8237 was given by PO Q1D × 3 weeks, vincristine and rituximab by IV Q1W × 4 weeks. MV1 represents the phase of tumor regression while MV2 represents the phase of lymphoma relapse. Tumor burdens were measured, graphed and represented as mean ± S.E.M. (B). Kaplan-Meier survival curves show overall survival differences between MVR in comparison to control, MR and MV.